Quanterix

  • Develops ultrasensitive single-molecule array (SIMOA) technology for clinical and research applications, offering ~1,000× sensitivity improvement over current standard ELISA tests
  • Primarily targets the biopharmaceutical research market in areas like neurology, oncology, cardiology, infectious d...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

SnapDNA

Company Profile | May 13, 2022

​​​​​Develops a rapid pathogen detection platform,TrueRapid; the system works by selectively capturing only live pathogenic bacteria cells by binding to aptamers Claims the system is capable of delivering quantitative analysis for the presence of food pathogens in 20 minutes and reducing the ... Not part of subscription

ChipCare

Company Profile | March 23, 2022

ChipCare develops microfluidics‑based, handheld cell analyzers for cell, protein, and pathogen detection Competitive differentiation from portability, multiplexing, and lack of need for refrigeration, accomplished via their proprietary reagent drying process First‑generation platform screens ... Not part of subscription

SwissDeCode

Company Profile | April 06, 2022

Developer of DNAFoil, B3, and BEAMitup — rapid DNA tests for food authentication and compliance; intends to sell compliance‑as‑a‑service via BEAMitup and ISO17025 certificates Company utilizes library of 200,000 unique DNA fingerprints to create onsite DNA tests with results in 30 minutes ... Not part of subscription